Results 261 to 270 of about 1,451,495 (316)

HOST RESISTANCE TO CANCER*

Australian and New Zealand Journal of Surgery, 1967
Summary1. Experimental studies on immunity to tumours in animals show that tumour growth is modified by an immunological reaction provided that the immunological system of the host is intact and the tumour carries antigens which are different to those of the host and therefore recognizably “foreign.”2.
openaire   +2 more sources

Host Resistance Assays

2018
The goal of immunotoxicity testing is to obtain data useful for immunotoxicity safety assessment. Guidance in the performance of immunotoxicity safety evaluations is provided in documents from the US EPA for chemicals and the ICH S8 document for pharmaceuticals.
Stefanie C M, Burleson, Wendy Jo, Freebern, Florence G, Burleson, Gary R, Burleson, Victor J, Johnson, Robert W, Luebke   +5 more
openaire   +2 more sources

Neutrophil function and host resistance

Infection, 1979
The part played by the phagocytic cells against invading pathogens has been known since the work of Metchnikoff nearly a century ago. This review deals primarily with the role of the neutrophilic polymorphonuclear leukocyte in host defense against microbial infections.
B, Zakhireh, L H, Block, R K, Root
openaire   +2 more sources

Enterobacteria and host resistance to infection

Mammalian Genome, 2018
Enterobacteriaceae are a large family of Gram-negative, non-spore-forming bacteria. Although many species exist as part of the natural flora of animals including humans, some members are associated with both intestinal and extraintestinal diseases. In this review, we focus on members of this family that have important roles in human disease: Salmonella,
Eugene Kang, Alanna Crouse, Lucie Chevallier, Stéphanie M. Pontier, Ashwag Alzahrani, Navoun Silué, François-Xavier Campbell-Valois, Xavier Montagutelli, Samantha Gruenheid, Danielle Malo   +9 more
openaire   +2 more sources

Glycolipids as host resistance stimulators

Journal of Medicinal Chemistry, 1990
6-(5-Cholesten-3 beta-yloxy)hexyl 1-thio-beta-D-mannopyranoside (L-644,257) enhances natural host resistance in cyclophosphamide-treated mice against Pseudomonas aeruginosa in a dose-dependent manner. It is active sc, im, and ip but not orally. L-644,257 is substantially more protective against P. aeruginosa than its alpha anomer.
M M, Ponpipom, W K, Hagmann, L A, O'Grady, J J, Jackson, D D, Wood, H J, Zweerink   +5 more
openaire   +2 more sources

HOST DEFENSES AND BACTERIAL RESISTANCE

Obstetrics and Gynecology Clinics of North America, 1992
The amount of knowledge and understanding about the human immune system has expanded rapidly in the past several decades. The ability of the physician to care for pregnant women, specifically those with infectious diseases, can be enhanced through a basic understanding of host defenses and the normal alterations of these defenses encountered during ...
openaire   +2 more sources

Arboviruses: Transmission and Host Resistance

Critical Reviews in Eukaryotic Gene Expression
In this review, there is a complete description of the classes of arboviruses, their evolutionary process, virus characterization, disease transmission methods; it also describes about the vectors involved in transmission and their mood of transmission, both biologically as well as non-biologically and, about host, the resistance mechanism in host, and
Sidra, Anwar, Bilal, Ahmed, Muhammad Imran, Qadir   +2 more
openaire   +2 more sources

HOST RESISTANCE TO INTRAAMNIOTIC INFECTION

Obstetrical & Gynecological Survey, 1975
In this review the mechanisms whereby amniotic fluid serves to protect the fetus from microbial disease have considered. It appears from the data reviewed that the principal mode of antibacterial action of amniotic fluid is bacteriostasis. Thus, the host is able to cope with a small number of organisms introduced into the amniotic cavity; however when ...
B, Larsen, R P, Galask
openaire   +2 more sources

The estimation of host-resistance in cancer

Medical Hypotheses, 1985
From the third year after its clinical diagnosis and onward the cancer hazard rate continuously declines. This phenomenon is common to all cancers irrespective of stage, and far less pronounced in other chronic diseases. It is so typical of cancer as to be regarded as a "law of the improving chances of the cancer patient".
openaire   +2 more sources